Alnylam Pharmaceuticals, Inc. (LON:0HD2)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 21.91B -48.8% |
| Revenue (ttm) | 3.62B +95.1% |
| Net Income | 583.90M |
| EPS | 4.24 |
| Shares Out | n/a |
| PE Ratio | 37.52 |
| Forward PE | 18.55 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 228 |
| Open | 224.68 |
| Previous Close | 218.97 |
| Day's Range | 218.80 - 224.76 |
| 52-Week Range | 199.81 - 500.21 |
| Beta | 0.28 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 30, 2026 |
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amylo... [Read more]
News
Alnylam price target lowered to $325 from $400 at Evercore ISI
Evercore ISI lowered the firm’s price target on Alnylam (ALNY) to $325 from $400 and keeps an Outperform rating on the shares.
ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law
LOS ANGELES, Aug. 4, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alnyl...
Alnylam price target lowered to $455 from $485 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Alnylam (ALNY) to $455 from $485 and keeps a Buy rating on the shares. Following the $200M midpoint reduction in full-year 2026…
Alnylam price target lowered to $315 from $410 at Truist
Truist lowered the firm’s price target on Alnylam (ALNY) to $315 from $410 and keeps a Buy rating on the shares. The outlook was tempered after weaker Amvuttra sales and…
Alnylam upgraded to Strong Buy from Outperform at Raymond James
Raymond James upgraded Alnylam (ALNY) to Strong Buy from Outperform with an unchanged price target of $420. The firm cites valuation for the upgrade with the shares down 35% since…
Alnylam price target lowered to $340 from $380 at Citi
Citi lowered the firm’s price target on Alnylam (ALNY) to $340 from $380 and keeps a Buy rating on the shares. The firm updated the company’s model post the Q2…
Alnylam price target lowered to $450 from $527 at Barclays
Barclays analyst Eliana Merle lowered the firm’s price target on Alnylam (ALNY) to $450 from $527 and keeps an Overweight rating on the shares. The company reported a “disappointing” quarter…
Alnylam price target lowered to $346 from $410 at BofA
BofA lowered the firm’s price target on Alnylam (ALNY) to $346 from $410 and keeps a Buy rating on the shares. While the firm continues to see ATTR-CM as a…
Alnylam price target lowered to $420 from $468 at Raymond James
Raymond James analyst Martin Auster lowered the firm’s price target on Alnylam (ALNY) to $420 from $468 and keeps an Outperform rating on the shares. Alnylam lowered 2026 TTR franchise…
Alnylam price target lowered to $350 from $500 at Oppenheimer
Oppenheimer lowered the firm’s price target on Alnylam (ALNY) to $350 from $500 and keeps an Outperform rating on the shares. The firm notes management’s $200M cut to 2026 TTR…
Alnylam price target lowered to $375 from $400 at JPMorgan
JPMorgan lowered the firm’s price target on Alnylam (ALNY) to $375 from $400 and keeps an Overweight rating on the shares.
Alnylam price target lowered to $300 from $400 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Alnylam (ALNY) to $300 from $400 and keeps an Equal Weight rating on the shares. Total TTR sales of $1.03B for the…
Alnylam price target lowered to $318 from $444 at Stifel
Stifel analyst Paul Matteis lowered the firm’s price target on Alnylam (ALNY) to $318 from $444 and keeps a Buy rating on the shares.
Alnylam Pharmaceuticals Earnings Call Transcript: Q2 2026
Q2 net product revenues surged 74% year-over-year to $1.2 billion, led by AMVUTTRA’s strong first-line growth and robust U.S. and international demand. 2026 revenue guidance was revised down by $200 million due to normalized second-line demand, but long-term growth targets remain intact, supported by favorable market dynamics and pipeline progress.
Alnylam Pharmaceuticals Earnings release: Q2 2026
Alnylam Pharmaceuticals released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Alnylam Pharmaceuticals Quarterly report: Q2 2026
Alnylam Pharmaceuticals has published its Q2 2026 quarterly earnings report on July 30, 2026.
Alnylam Pharmaceuticals Slides: Q2 2026
Alnylam Pharmaceuticals has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended J...
Alnylam price target lowered to $400 from $420 at JPMorgan
JPMorgan lowered the firm’s price target on Alnylam (ALNY) to $400 from $420 and keeps an Overweight rating on the shares. The firm updated the company’s model. Published first on…
Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter end...
Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today shared advances across its growing neuroscience portfolio at the Alzheimer...
AstraZeneca Stock and Partner Ionis Sink After Trial Failure. Alnylam Soars.
AstraZeneca and California-based biotech Ionis Pharmaceuticals announce a late-stage trial failure for their gene silencing drug, Wainua.
Alnylam Pharmaceuticals Transcript: Study update
ALN-6400, an RNAi therapy targeting plasminogen, is advancing through phase I and II studies for HHT and VWD, aiming to provide durable, safe bleed protection with infrequent dosing. Early data show strong mechanistic rationale, promising safety, and potential to address significant unmet needs in these rare bleeding disorders.